Name:
16123-237403-2-PB.pdf
Size:
3.591Mb
Format:
PDF
Description:
full text open access article
Authors
Itkonen, HBrown, Michael D
Urbanucci, A
Tredwell, G
Ho Lau, C
Barfeld, S
Hart, C
Guldvik, I
Takhar, M
Heemers, H
Erho, N
Bloch, K
Davicioni, E
Derua, R
Waelkens, E
Mohler, J
Clarke, Noel W
Swinnen, J
Keun, H
Rekvig, O
Mills, I
Affiliation
Prostate Cancer Research Group, Centre for Molecular Medicine Norway, University of Oslo, Oslo, NorwayIssue Date
2017-03-11
Metadata
Show full item recordAbstract
Prostate cancer is the most common male cancer and androgen receptor (AR) is the major driver of the disease. Here we show that Enoyl-CoA delta isomerase 2 (ECI2) is a novel AR-target that promotes prostate cancer cell survival. Increased ECI2 expression predicts mortality in prostate cancer patients (p = 0.0086). ECI2 encodes for an enzyme involved in lipid metabolism, and we use multiple metabolite profiling platforms and RNA-seq to show that inhibition of ECI2 expression leads to decreased glucose utilization, accumulation of fatty acids and down-regulation of cell cycle related genes. In normal cells, decrease in fatty acid degradation is compensated by increased consumption of glucose, and here we demonstrate that prostate cancer cells are not able to respond to decreased fatty acid degradation. Instead, prostate cancer cells activate incomplete autophagy, which is followed by activation of the cell death response. Finally, we identified a clinically approved compound, perhexiline, which inhibits fatty acid degradation, and replicates the major findings for ECI2 knockdown. This work shows that prostate cancer cells require lipid degradation for survival and identifies a small molecule inhibitor with therapeutic potential.Citation
Lipid degradation promotes prostate cancer cell survival. 2017 OncotargetJournal
OncotargetDOI
10.18632/oncotarget.16123PubMed ID
28415728Type
ArticleLanguage
enISSN
1949-2553ae974a485f413a2113503eed53cd6c53
10.18632/oncotarget.16123
Scopus Count
Collections
Related articles
- The lipid-metabolism enzyme ECI2 reduces neutrophil extracellular traps formation for colorectal cancer suppression.
- Authors: Chen L, Dai P, Liu L, Chen Y, Lu Y, Zheng L, Wang H, Yuan Q, Li X
- Issue date: 2024 Aug 21
- HNF1B, EZH2 and ECI2 in prostate carcinoma. Molecular, immunohistochemical and clinico-pathological study.
- Authors: Dundr P, Bártů M, Hojný J, Michálková R, Hájková N, Stružinská I, Krkavcová E, Hadravský L, Kleissnerová L, Kopejsková J, Hiep BQ, Němejcová K, Jakša R, Čapoun O, Řezáč J, Jirsová K, Franková V
- Issue date: 2020 Sep 1
- Lipid Uptake Is an Androgen-Enhanced Lipid Supply Pathway Associated with Prostate Cancer Disease Progression and Bone Metastasis.
- Authors: Tousignant KD, Rockstroh A, Taherian Fard A, Lehman ML, Wang C, McPherson SJ, Philp LK, Bartonicek N, Dinger ME, Nelson CC, Sadowski MC
- Issue date: 2019 May
- ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer.
- Authors: Centenera MM, Scott JS, Machiels J, Nassar ZD, Miller DC, Zinonos I, Dehairs J, Burvenich IJG, Zadra G, Chetta PM, Bango C, Evergren E, Ryan NK, Gillis JL, Mah CY, Tieu T, Hanson AR, Carelli R, Bloch K, Panagopoulos V, Waelkens E, Derua R, Williams ED, Evdokiou A, Cifuentes-Rius A, Voelcker NH, Mills IG, Tilley WD, Scott AM, Loda M, Selth LA, Swinnen JV, Butler LM
- Issue date: 2021 Apr 1
- SREBF1 Activity Is Regulated by an AR/mTOR Nuclear Axis in Prostate Cancer.
- Authors: Audet-Walsh É, Vernier M, Yee T, Laflamme C, Li S, Chen Y, Giguère V
- Issue date: 2018 Sep